文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

基于剂量的影像组学(剂量组学)预测前列腺癌IMRT后生化失败

Dose-Based Radiomic Analysis (Dosiomics) for Intensity Modulated Radiation Therapy in Patients With Prostate Cancer: Correlation Between Planned Dose Distribution and Biochemical Failure.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-10-24

本研究纳入489例接受调强放疗的局限期前列腺癌患者,从 prostate、CTV 和 PTV 的剂量分布中提取2475个剂量组学特征,在342例训练队列构建生化复发(BCR)预测模型,并在147例验证队列用 C-index 验证。

要点

  • CTV 剂量组学特征与前列腺癌IMRT后生化复发显著相关。
  • 剂量组学模型优于传统剂量学模型但未优于临床模型。
  • 临床变量联合剂量组学特征可提升预测性能。

核心结论

  • CTV 提取的剂量组学特征与前列腺癌患者生化复发显著相关,剂量组学模型优于传统剂量指标模型,提示需要新的治疗计划质量评价指标。

研究设计与样本

  • 回顾性纳入489例接受调强放疗的局限期前列腺癌患者(BCR 96例,无BCR 393例),从 prostate、CTV 和 PTV 剂量分布提取2475个剂量组学特征,在342例训练队列构建模型,在147例验证队列用 C-index 验证。

主要发现

  • 剂量组学模型优于剂量学模型和影像组学模型,但未优于临床模型。

临床怎么用

  • CTV 剂量组学特征可作为前列腺癌IMRT后生化复发的预后参考,联合临床变量可能改善风险分层。
  • 剂量组学能否纳入临床工作流或临床试验尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although radiation therapy is one of the most significant treatment modalities for localized prostate cancer, the prognostic factors for biochemical recurrence (BCR) regarding the treatment plan are unclear. We aimed to develop a novel dosiomics-based prediction model for BCR in patients with prostate cancer and clarify the correlations between the dosimetric factors and BCR. METHODS AND MATERIALS: This study included 489 patients with localized prostate cancer (BCR: 96; no-BCR: 393) who received intensity modulated radiation therapy. A total of 2475 dosiomic features were extracted from the dose distributions on the prostate, clinical target volume (CTV), and planning target volume. A prediction model for BCR was trained on a training cohort of 342 patients. The performance of this model was validated using the concordance index (C-index) in a validation cohort of 147 patients. Another model was constructed using clinical variables, dosimetric parameters, and radiomic features for comparisons. Kaplan-Meier curves with log-rank analysis were used to assess the univariate discrimination based on the predictive dosiomic features. RESULTS: The dosiomic feature derived from the CTV was significantly associated with BCR (hazard ratio, 0.73; 95% CI, 0.57-0.93; P = .01). Although the dosiomics model outperformed the dosimetric and radiomics models, it did not outperform the clinical model. The performance significantly improved by combining the clinical variables and dosiomic features (C-index: 0.67; 95% CI, 0.65-0.68; P < .0001). The predictive dosiomic features were used to distinguish high-risk and low-risk patients (P < .05). CONCLUSIONS: The dosiomic feature extracted from the CTV was significantly correlated with BCR in patients with prostate cancer, and the dosiomics model outperformed the model with conventional dose indices. Hence, new metrics for evaluating the quality of a treatment plan are warranted. Moreover, further research should be conducted to determine whether dosiomics can be incorporated in a clinical workflow or clinical trial.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Murakami Y, Soyano T, Kozuka T, et al. Dose-Based Radiomic Analysis (Dosiomics) for Intensity Modulated Radiation Therapy in Patients With Prostate Cancer: Correlation Between Planned Dose Distribution and Biochemical Failure. Int J Radiat Oncol Biol Phys. 2021. PMID: 34706278. doi:10.1016/j.ijrobp.2021.07.1714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。